Neurotherapeutics e00712 (2025) doi:10.1016/j.neurot.2025.e00712
In the SURMOUNT-5 trial, published in the New England Journal of Medicine, patients receiving tirzepatide had a mean percent decrease in body weight of 20.2%, compared with 13.7% for those receiving semaglutide,over 72 weeks
The choice between them depends on individual health profiles, physician recommendations, and, importantly, cost considerations
Support consistently answered in under a minute during my checks, and the help center covers everything from payout thresholds to device troubleshooting
Through these roles, Harris built a reputation for being a tough but fair advocate
During your appointment, we review your health history, complete comprehensive lab testing, and discuss your goals before starting semaglutide safely